ClinicalTrials.gg
CompletedNCT02183168Updated Nov 24, 2023

Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis

A Phase 3 interventional study of Meloxicam suppository and Meloxicam tablet in Spondylitis, Ankylosing, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 13 years after the study started (first participant enrolled Jul 2001, registered Jul 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with Indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis

02

Conditions studied

  • Spondylitis, Ankylosing
03

In context

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

This study's enrollment of 192 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.

Browse Spondylitis, Ankylosing studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active ankylosing spondylitis (pain rated >= 40 mm on a VAS and increased of at least 30% after nonsteroidal anti-inflammatory drugs (NSAIDs) wash-out)), without peripheral arthritis and inflammatory bowel disease

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Meloxicam suppository

    Drug: Meloxicam suppository

  • Experimental
    Meloxicam tablet

    Drug: Meloxicam tablet

  • Active comparator
    Indomethacin suppository

    Drug: Indomethacin

06

What researchers measure

Primary outcomes

  1. Overall pain during the previous 48 hours assessed on a Visual Analogue Scale (VAS)

    Time frame: 6 weeks

  2. Functional Index of ankylosing spondylitis of Dougados

    Time frame: 6 weeks

  3. Overall assessment of disease activity by the patient on VAS

    Time frame: 6 weeks

Secondary outcomes

  1. Overall assessment of disease activity by the investigator on a VAS

    Time frame: 6 weeks

  2. Global efficacy assessed by the patient (verbal rating scale)

    Time frame: 6 weeks

  3. Global efficacy assessed by the investigator (verbal rating scale)

    Time frame: 6 weeks

  4. Duration of morning stiffness

    Time frame: 6 weeks

  5. Evaluation of spinal pain by the investigator (verbal rating scale)

    Time frame: 6 weeks

  6. Assessment of Schober test

    Time frame: 6 weeks

  7. Assessment of Chest expansion

    Time frame: 6 weeks

  8. Assessment of Fingers - to - floor test

    Time frame: 6 weeks

  9. Assessment of Night pain (verbal rating scale)

    Time frame: 6 weeks

  10. Total number of study withdrawals

    Time frame: 6 weeks

  11. Number of study withdrawals due to lack of efficacy

    Time frame: 6 weeks

  12. Assessment of Paracetamol consumption

    Time frame: 6 weeks

  13. Assessment of Patient status with regard to disease condition

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2001 to primary completion in May 2002, 10 months.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 10 months is below that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
StartActual
Jul 1, 2001
Primary completionActual
May 1, 2002
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183168
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jul 1, 2001
Primary completion
May 1, 2002
Last update
Nov 24, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion